医药导报2026，Vol.45Issue(3)：357-367,11.DOI:10.3870/j.issn.1004-0781.2026.03.001
江苏省成人2型糖尿病药物治疗路径专家共识(2025年版)
Expert Consensus on Pharmacotherapy Pathways for Type 2 Diabetes in Adults in Jiangsu Province(2025 Edition)
摘要
Abstract
Type 2 diabetes mellitus is a chronic metabolic disease characterized by a high prevalence rate,a significant disease burden,and the need for long-term standardized management.The latest national epidemiological data reveal that in Jiang-su Province in 2023,the age-standardized prevalence of diabetes has reached 16.35％,ranking among the highest among provin-cial-level administrative regions in China and highlighting the severe challenges of diabetes prevention and control in Jiangsu Province.Effective pharmacological treatment is crucial for controlling blood glucose levels,delaying complications,and improving patients'quality of life.Based on the latest domestic and international authoritative guidelines for the diagnosis and treatment of a-dult type 2 diabetes,this consensus focuses on the selection of pharmacological treatment strategies at different stages of disease progression.It refines the medication regimens recommended in the guidelines in the form of a structured pathway,clarifies the therapeutic positioning,target populations,dosage ranges,and administration regimens of various classes of hypoglycemic drugs,while emphasizing the standardization and timeliness of pharmacological treatment.The aim is to establish a standardized pharma-cological treatment pathway,bridge the gap between clinical guidelines and practice,provide clinicians with pathway-based treat-ment strategies,and offer solutions for rational drug use in clinical settings.关键词
2型糖尿病/药物治疗路径/降糖药物/合理用药/临床共识/慢性病管理Key words
Type 2 diabetes mellitus/Pharmacological treatment pathway/Hypoglycemic drugs/Rational drug use/Clin-ical consensus/Chronic disease management分类
医药卫生引用本文复制引用
江苏省研究型医院学会精益化用药研究与转化专业委员会,葛卫红,马建华..江苏省成人2型糖尿病药物治疗路径专家共识(2025年版)[J].医药导报,2026,45(3):357-367,11.基金项目
癌症、心脑血管、呼吸和代谢性疾病防治研究国家科技重大专项(2023ZD0508105) （2023ZD0508105）
江苏省药品临床综合评价项目(SYH-350-0184). （SYH-350-0184）
